17 results
Primary ObjectiveThe primary objective of this study is to assess whether the antidepressant response to IV ketamine can be maintained by minocycline compared to placebo.Secondary ObjectivesThe secondary objectives of this study are:* To investigate…
Can this effect be utilised clinically, especially in patients with major depressive disorder?
To study the effects of ARA290 on the cognitive and neural processing of emotions in healthy volunteers 7 days post-administration.
The objective of the study is to evaluate various doses of SSR125543 in first patients (outpatients with a major depressive disorder), evaluate collected information concerning tolerability, efficacy en safety. The same infomation will be evaluated…
The primary aim of ICT4D is to design an intelligent monitoring and selfhelpsystem for use in Primary Care (Moodbuster). In this pilot study the feasibility and the usability if this intervention is tested among patients suffering from minor and…
Primary objective:To show that concomitant use of telaprevir (1125 mg BID) does not lead to a relevant decrease (> 20%) in the paroxetine parameter AUC0-24h compared to paroxetine alone.Secondary objectives:To determine the ratio of the…
The current pilot study aims to examine the feasibility of the module when added to an existing problem-solving intervention, *Alles onder Controle*, for reducing symptoms of anxiety and depression. Additionally, we aim to get first insight in…
Primary research question:- Does treatment with drugs modulating vasoconstriction, i.e. COX-inhibitors (acetaminophen) or calcium-antagonists (nimodipine), improve electrographic postictal phenomena?Secondary research questions:- Does treatment with…
Evaluation of the feasibility of a trial on the efficacy of oral esketamine for the treatment of depression and/or demoralization in patients with advanced cancer who receive palliative care.
The main purpose of the study is to support dose selection for future Phase 3 clinical trials by evaluating the efficacy and safety of four MIJ821 doses (0.0048, 0.016, 0.048 and 0.16 mg/kg) administered every other week by intravenous infusion on…
To investigate whether mifepristone (7-day, 1200 mg/day) added to treatment as usual (TAU), is more efficacious than placebo in reducing depressive symptom severity (Inventory of Depressive Symptoms-Self Rated questionnaire; IDS-SR) in patients with…
The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg or 10 mg) compared to 1 mg, administered under supportive conditions to adult participants with TRD, in improving depressive symptoms, as assessed by the change in…
The primary aim of this study is to investigate the feasibility, acceptability and user-friendliness of implementing PM+ in Dutch prisons. This is a version of PM+ that is specifically adapted to the prisoner population and prison context. The…
The primary objective of this study is to assess the long-term efficacy of COMP360 with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg…
In a randomized control trial (RCT) with mothers with postpartum depressive symptoms the following main hypotheses will be tested:• Oxytocin will promote more sensitive caregiving during mother-infant interactions and while interacting with a life-…
To determine the efficacy of a single day individualized dosing regimen (IDR) of GH001 compared with placebo in improving depressive symptoms as assessed by MADRS in patients with treatment-resistant depression (TRD) at the end of the 7-day double-…
Main research question:Does group-based schema therapy result in a reduction of depressive symptoms when comparing symptom change during the treatment to patients* baseline symptom level?Sub research questions:Does group-based schema therapy result…